Matrix metalloproteinases and their clinical relevance in urinary bladder cancer

Nature Reviews Urology

Volumn 8, Issue 5, 2011, Pages 241-254

  Szarvas, Tibor ^a   Vom Dorp, Frank ^a   Ergün, Süleyman ^a   Rübben, Herbert ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FROZEN SECTION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW; TISSUE LEVEL; URINE LEVEL; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; URINARY BLADDER NEOPLASMS;

EID: 79955842460     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.44     Document Type: Review

References (130)

1. Aitken, K. J. & Bägli, D. J. The bladder extracellular matrix. Part I: architecture, development and disease. Nat. Rev. Urol. 6, 596-611 (2009).
2. Chambers, A. F., Groom A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002). (Pubitemid 37328923)
3. Deryugina, E. I. & Quigley, J. P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9-34 (2006). (Pubitemid 43723979)
4. Page-McCaw, A., Ewald, A. J. & Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221-233 (2007).
5. Haas, T. L. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 279, 1540-1547 (2000).
6. Fata, J. E., Ho, A. T., Leco, K. J., Moorehead, R. A. & Khokha, R. Cellular turnover and extracellular matrix remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors. Cell. Mol. Life Sci. 57, 77-95 (2000). (Pubitemid 30105331)
7. Burrage, P. S., Mix, K. S. & Brinckerhoff, C. E. Matrix metalloproteinases: role in arthritis. Front. Biosci. 11, 529-543 (2006). (Pubitemid 43258162)
8. Liu, P., Sun, M. & Sader, S. Matrix metalloproteinases in cardiovascular disease. Can. J. Cardiol. 22, 25-30 (2006).
9. Westermarck, J. & Kähäri, V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13, 781-792 (1999). (Pubitemid 29220691)
10. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174 (2002). (Pubitemid 37328786)
11. Nagase, H. & Woessner, J. F. Jr. Matrix metalloproteinases. J. Biol. Chem. 274, 21491-21494 (1999).
12. Bode, W. & Maskos, K. Structural studies on MMPs and TIMPs. Methods Mol. Biol. 151, 45-77 (2001).
13. Yan, C. & Boyd, D. D. Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 211, 19-26 (2007). (Pubitemid 46363892)
14. Fanjul-Fernández, M., Folgueras, A. R., Cabrera, S. & López-Otín, C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 1803, 3-19 (2010).
15. Chicoine, E. et al. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem. Biophys. Res. Commun. 297, 765-772 (2002). (Pubitemid 35230316)
16. Shukeir, N., Pakneshan, P., Chen, G., Szyf, M. & Rabbani, S. A. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66, 9202-9210 (2006). (Pubitemid 44521141)
17. Hadler-Olsen, E., Fadnes, B., Sylte, I., Uhlin-Hansen, L. & Winberg J. O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 278, 28-45 (2011)
18. Kähäri, V. M. & Saarialho-Kere, U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann. Med. 31, 34-45 (1999). (Pubitemid 29134483)
19. Cruz-Munoz, W. & Khokha, R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit. Rev. Clin. Lab. Sci. 45, 291-338 (2008). (Pubitemid 351883130)
20. Thomas, P., Khokha, R., Shepherd, F. A., Feld, R. & Tsao, M. S. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol. 190, 150-156 (2000). (Pubitemid 30082487)
21. de Vicente, J. C., Fresno, M. F., Villalain, L., Vega, J. A. & López, Arranz, J. S. Immunoexpression and prognostic significance of TIMP-1 and-2 in oral squamous cell carcinoma. Oral Oncol. 41, 568-579 (2005). (Pubitemid 40828873)
22. Rhee, J. S., Diaz, R., Korets, L., Hodgson, J. G. & Coussens, L. M. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res. 64, 952-961 (2004).
23. Kong, Y. et al. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Res. 64, 5795-5803 (2004). (Pubitemid 39099306)
24. Baker, A. H., Edwards, D. R. & Murphy, G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115, 3719-3727 (2002). (Pubitemid 35203598)
25. Aparicio, T., Kermorgant, S., Dessirier, V., Lewin, M. J. & Lehy, T. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 20, 1445-1451 (1999). (Pubitemid 29385428)
26. Haq, M., Shafii, A., Zervos, E. E. & Rosemurgy, A. S. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 60, 3207-3211 (2000). (Pubitemid 30407918)
27. Nelson, A. R., Fingleton, B. & Rothenberg, M. L. Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18, 1135-1149 (2000). (Pubitemid 30123793)
28. Itoh, T. et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis 17, 177-181 (1999). (Pubitemid 29335445)
29. Szabova, L., Chrysovergis, K., Yamada, S. S. & Holmbeck, K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 27, 3274-3281 (2008). (Pubitemid 351733384)
30. Itoh, T. et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58, 1048-1051 (1998). (Pubitemid 28182477)
31. Kupferman, M. E. et al. Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Am. J. Pathol. 157, 1777-1783 (2000).
32. Lochter, A. et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139, 1861-1872 (1997). (Pubitemid 28079248)
33. Vihinen, P. & Kähäri, V. M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99, 157-166 (2002). (Pubitemid 34309470)
34. Roy, R., Yang, J. & Moses, M. A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27, 5287-5297 (2009).
35. Sier, C. F. et al. Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biol. 27, 267-271 (2008). (Pubitemid 351384767)
36. Harper, J. & Moses, M. A. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 96, 223-268 (2006).
37. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744 (2000).
38. Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D. & Iruela-Arispe, M. L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors J. Cell. Biol. 169, 681-691 (2005). (Pubitemid 41002860)
39. Whitelock, J. M., Murdoch A. D., Iozzo, R. V. & Underwood, P. A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 271, 10079-10086 (1996). (Pubitemid 26131567)
40. Du, R. et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206-220 (2008). (Pubitemid 351318372)
41. Heljasvaara, R. et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp. Cell Res. 307, 292-304 (2005). (Pubitemid 40799357)
42. Chang J. H., Javier, J. A., Chang, G. Y., Oliveira, H. B. & Azar, D. T. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett. 579, 3601-3606 (2005). (Pubitemid 40897698)
43. Mitsiades, N., Yu, W. H., Poulaki, V., Tsokos, M. & Stamenkovic, I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61, 577-581 (2001). (Pubitemid 32128617)
44. Almendro, V. et al. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS ONE 4, 4728 (2009).
45. Vargo-Gogola, T., Fingleton, B., Crawford, H. C. & Matrisian, L. M. Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. Cancer Res. 62, 5559-5563 (2002).
46. Liu, H. et al. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci. 99, 2185-2192 (2008).
47. Noë, V. et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 114, 111-118 (2001). (Pubitemid 32120080)
48. Cowden Dahl, K. D. et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res. 68, 4606-4613 (2008).
49. Radisky, D. C. et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436, 123-127 (2005). (Pubitemid 40966197)
50. Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A. & Klagsbrun, M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. 272, 31730-31737 (1997). (Pubitemid 28013322)
51. Kivisaari, A. K. et al. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br. J. Dermatol. 163, 726-735 (2010).
52. Nakamura, M. et al. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem. Biophys. Res. Commun. 333, 1011-1016 (2005). (Pubitemid 40854257)
53. Mañes, S. et al. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem. 272, 25706-25712 (1997). (Pubitemid 27438888)
54. Dormán, G. et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 70, 949-964 (2010).
55. Verheijen, J. H. et al. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem. J. 323, 603-609 (1997). (Pubitemid 27202329)
56. Scherer, R. L. & McIntyre, J. O. Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev. 27, 679-690 (2008).
57. Jung, K., Klotzek, S., Stephan, C., Mannello, F. & Lein, M. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin. Chem. 54, 772-773 (2008).
58. Mannello, F., Tonti, G. A., Tanus-Santos, J. E. & Gerlach, R. F. Silicate increases the release of MMP-9 forms in peripheral blood: why gelatin zymography differs significantly in citrate plasma and serum obtained with or without clot activators. Clin. Chem. 53, 1981-1982 (2007). (Pubitemid 350036049)
59. Smith, E. R., Zurakowski, D., Saad, A., Scott, R. M. & Moses, M. A. Urinary biomarkers predict brain tumor presence and response to therapy. Clin. Cancer Res. 14, 2378-2386 (2008). (Pubitemid 351551071)
60. Ozdemir, E., Kakehi, Y., Okuno, H. & Yoshida, O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J. Urol. 161, 1359-1363 (1999). (Pubitemid 29426157)
61. Nakopoulou, L. et al. MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl. Immunohistochem. Mol. Morphol. 9, 130-137 (2001). (Pubitemid 32477200)
62. Choi, Y. D. et al. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma. J. Urol. 177, 1174-1178 (2007). (Pubitemid 46216371)
63. Durkan, G. C. et al. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin. Cancer Res. 7, 3450-3456 (2001). (Pubitemid 33069980)
64. Staack, A., Badendieck, S., Schnorr, D., Loening, S. A. & Jung, K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol. 6, 19 (2006).
65. Svatek, R. S. et al. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer 116, 4513-4519 (2010).
66. Nutt, J. E., Mellon, J. K., Qureshi, K. & Lunec, J. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br. J. Cancer 78, 215-220 (1998). (Pubitemid 28302259)
67. Itoh, M. et al. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25, 1195-1204 (2006).
68. Davies, B. et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53, 5365-5369 (1993). (Pubitemid 23342150)
69. Mohammad, M. A., Ismael, N. R., Shaarawy, S. M. & El-Merzabani, M. M. Prognostic value of membrane type 1 and 2 matrix metalloproteinase expression and gelatinase A activity in bladder cancer. Int. J. Biol. Markers 25, 69-74 (2010).
70. Wallard, M. J. et al. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br. J. Cancer 94, 569-577 (2006). (Pubitemid 43289762)
71. Grignon, D. J. et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 56, 1654-1659 (1996). (Pubitemid 26104031)
72. Vasala, K., Pääkkö, P. & Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 62, 952-957 (2003). (Pubitemid 37421256)
73. Kanayama, H. et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82, 1359-1366 (1998). (Pubitemid 28155399)
74. Hara, I., Miyake, H., Hara, S., Arakawa, S. & Kamidono, S. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J. Urol. 165, 1769-1772 (2001). (Pubitemid 32410306)
75. Gohji, K. et al. Elevation of serum levels of matrix metalloproteinase-2 and-3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78, 2379-2387 (1996). (Pubitemid 26392839)
76. Vasala, K. & Turpeenniemi-Hujanen, T. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin. Biochem. 40, 640-644 (2007). (Pubitemid 46829065)
77. Vasala, K., Kuvaja, P. & Turpeenniemi-Hujanen, T. Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer. Tumour Biol. 29, 279-286 (2008).
78. Sier, C. F. et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res. 6, 2333-2340 (2000). (Pubitemid 30399200)
79. Gerhards, S. et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57, 675-679 (2001).
80. Eissa, S. et al. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur. Urol. 52, 1388-1396 (2007).
81. Miyake, H. et al. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J. Urol. 157, 2351-2355 (1997). (Pubitemid 27208720)
82. Nutt, J. E., Durkan, G. C, Mellon, J. K. & Lunec, J. Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int 91, 99-104 (2003).
83. Shin, K. Y. et al. Effects of tumor necrosis factor-α and interferon-γ on expressions of matrix metalloproteinase-2 and-9 in human bladder cancer cells. Cancer Lett. 159, 127-134 (2000).
84. 2 on MMP-2 production and activity in highly metastatic human bladder carcinoma cell line 5637. Cancer Invest. 27, 568-574 (2009).
85. Lee, S. J., Park, S. S., Lee, U. S., Kim, W. J. & Moon, S. K. Signaling pathway for TNF-α-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Int Immunopharmacol. 8, 1821-1826 (2008).
86. Chang, H. R. et al. The suppressive effect of Rho kinase inhibitor, Y-27632, on oncogenic Ras/RhoA induced invasion/migration of human bladder cancer TSGH cells. Chem. Biol. Interact 183, 172-180 (2010).
87. Kumar, B. et al. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity Cancer Res. 70, 832-841 (2010).
88. Lynch, C C et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7, 485-496 (2005). (Pubitemid 40719131)
89. Maurel, J. et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int. J. Cancer 121, 1066-1071 (2007). (Pubitemid 47101644)
90. Ramankulov, A. et al. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cel carcinomas. Cancer Sci. 99, 1188-1194 (2008). (Pubitemid 351676631)
91. Szarvas, T. et al. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy Int. J. Cancer 128, 1486-1492 (2010).
92. Szarvas, T. et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci. 101, 1300-1308 (2010).
93. Szarvas, T. et al. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int. doi:10.1111/j.1464-410X.2010.09625.x.
94. Szarvas, T. et al. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol. Oncol. Res. doi:10.1007/s12253-010-9320-4.
95. Guan, K. P, Ye, H. Y., Yan, Z., Wang, Y & Hou, S. K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 61, 719-723 (2003). (Pubitemid 36384961)
96. Durkan, G. C et al. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin. Cancer Res. 9, 2576-2582 (2003). (Pubitemid 36842099)
97. Vasala, K., Pääkko, P. & Turpeenniemi-Hujanen, T. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis. Anticancer Res. 28, 1757-1761 (2008).
98. Donmez, G. et al. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol. Res. Pract. 205, 854-857 (2009).
99. Slaton, J. W. et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J. Urol. 171, 570-574 (2004). (Pubitemid 38090431)
100. Bianco, F. J. Jr et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin. Cancer Res. 4, 3011-3016 (1998). (Pubitemid 29001475)
101. Offersen, B. V. et al. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol. 49, 1283-1287 (2010).
102. Moses, M. A. et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58, 1395-1399 (1998). (Pubitemid 28193598)
103. Roy, R. et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin. Cancer Res. 14, 6610-6617 (2008).
104. Ongusaha, P. P. et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 64, 5283-5290 (2004). (Pubitemid 39006548)
105. Lee, S. J. et al. Activation of matrix metalloproteinase-9 by TNF-α in human urinary bladder cancer HT1376 cells: the role of MAP kinase signaling pathways. Oncol. Rep. 19, 1007-1013 (2008).
106. Inoue, K. et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 60, 2290-2299 (2000). (Pubitemid 30225196)
107. Chang, C. C. et al. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res. 68, 6281-6291 (2008).
108. Xue, Y. J., Lu, Q. & Sun, Z. X. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med. Oncol. doi:10.1007/s12032-010-9582-4.
109. Saeb-Parsy, K. et al. MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3. Br. J. Cancer 99, 663-669 (2008).
110. Seargent, J. M. et al. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology 65, 815-820 (2005). (Pubitemid 40523044)
111. Mueller, J., Steiner, C. & Höfler, H. Stromelysin-3 expression in noninvasive and invasive neoplasms of the urinary bladder. Hum. Pathol. 31, 860-865 (2000). (Pubitemid 30480459)
112. Rodríguez Faba, O. et al. Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters. Urol. Int. 78, 140-144 (2007). (Pubitemid 46239134)
113. Naruo, S. et al. Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int. J. Urol. 1, 228-231 (1994). (Pubitemid 2156451)
114. Gakiopoulou, H. et al. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin. Cancer Res. 9, 5573-5581 (2003). (Pubitemid 37499477)
115. Hayakawa, T., Yamashita, K., Ohuchi, E. & Shinagawa, A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 107, 2373-2379 (1994). (Pubitemid 24292486)
116. Nicholson, B. E. et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res. 64, 7813-7821 (2004). (Pubitemid 39446914)
117. Chaffer, C. L. et al. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clin. Exp. Metastasis 22, 115-125 (2005). (Pubitemid 41185849)
118. Eissa, S., Shabayek, M. I., Ismail, M. F., El-Allawy, R. M. & Hamdy, M. A. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer. IUBMB Life 62, 394-399 (2010).
119. Kader, A. K. et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 66, 11644-11648 (2006). (Pubitemid 46094175)
120. Kader, A. K. et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin. Cancer Res. 13, 2614-2620 (2007). (Pubitemid 46788027)
121. Tasci, A. I. et al. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int. 101, 503-507 (2008). (Pubitemid 351160936)
122. Srivastava, P., Mandhani, A., Kapoor, R. & Mittal, R. D. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann. Surg. Oncol. 17, 3068-3075 (2010).
123. Srivastava, P., Gangwar, R., Kapoor, R. & Mittal, R. D. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis. Markers 29, 37-46 (2010).
124. Mitra, A. P. & Cote, R. J. Molecular screening for bladder cancer: progress and potential. Nat. Rev. Urol. 7, 11-20 (2010).
125. Fernández, C. A. et al. A novel approach to using matrix metalloproteinases for bladder cancer. J. Urol. 182, 2188-2194 (2009).
126. Leissner, J. et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J. Urol. 171, 139-144 (2004). (Pubitemid 37549109)
127. Shariat, S. F. et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112, 315-325 (2008).
128. Nemunaitis, J. et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. 4, 1101-1109 (1998). (Pubitemid 28213319)
129. Pavlaki, M. & Zucker, S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 22, 177-203 (2003). (Pubitemid 36561057)
130. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002). (Pubitemid 34270240)